RIG-I Inhibitors
RIG-I inhibitors represent a diverse class of chemical compounds designed to modulate the activity of RIG-I, a pivotal sensor in the innate immune response against viral infections. While direct RIG-I inhibitors are limited, various chemicals offer insights into the intricate regulatory pathways governing RIG-I expression and function. BX795, a TBK1 inhibitor, directly interferes with RIG-I-mediated signaling by disrupting the phosphorylation and activation of IRF3, a downstream target of RIG-I. Similarly, BX-795 Hydrochloride provides a specific tool for investigating the role of TBK1 in RIG-I-mediated antiviral responses. Amlexanox and PS-1145 target IKKε and IKKα, respectively, upstream regulators of RIG-I, offering indirect modulation of RIG-I expression by suppressing NF-κB activation. These compounds provide insights into the interplay between IKKε/IKKα signaling and RIG-I-mediated antiviral pathways. Cytarabine, known for its role in nucleotide metabolism and protein synthesis, indirectly influence RIG-I by modulating the NF-κB pathway. This reveals crosstalk between cellular metabolism and innate immune signaling in the context of antiviral responses.
Ruxolitinib, a JAK inhibitor, indirectly influences RIG-I by targeting the JAK-STAT pathway, impacting the downstream signaling events. UNC1999, a histone methyltransferase inhibitor, explores the role of epigenetic regulation in RIG-I expression, highlighting links between chromatin dynamics and antiviral immune responses. BAY 11-7082 and BMS-345541, inhibitors of NF-κB activation and IKK-1, respectively, provide insights into the regulatory mechanisms linking NF-κB signaling and RIG-I-mediated antiviral responses. Nafamostat Mesylate, a serine protease inhibitor, indirectly modulates RIG-I by suppressing proteolytic activities involved in viral entry and innate immune responses. This compound sheds light on the crosstalk between protease activities and RIG-I function, offering avenues for modulating antiviral immune responses. In conclusion, RIG-I inhibitors, though limited in direct options, offer a diverse set of compounds to explore the complex regulatory mechanisms governing RIG-I activity and its impact on antiviral signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX795 is an inhibitor of TANK-binding kinase 1 (TBK1), a key component in the RIG-I signaling pathway. By inhibiting TBK1, BX795 disrupts the phosphorylation and activation of interferon regulatory factor 3 (IRF3), a downstream target of RIG-I. This direct inhibition impacts RIG-I-mediated signaling, influencing the production of type I interferons and pro-inflammatory cytokines in response to viral infection. | ||||||
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
Amlexanox inhibits the activity of IκB kinase ε (IKKε), an upstream regulator of RIG-I. By suppressing IKKε, Amlexanox interferes with the activation of nuclear factor kappa B (NF-κB), a pathway linked to RIG-I signaling. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $150.00 $263.00 $518.00 $731.00 $1461.00 | 1 | |
1-β-D-Arabinofuranosylcytosine, an antimetabolite used in cancer chemotherapy, indirectly influences RIG-I through modulation of the NF-κB pathway. By inhibiting DNA synthesis, 1-β-D-Arabinofuranosylcytosine affects the activation of NF-κB, a regulator of RIG-I expression. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||
IKK Inhibitor X | 431898-65-6 | sc-221742 | 5 mg | $352.00 | 3 | |
PS-1145 is an inhibitor of IκB kinase α (IKKα), an upstream regulator of RIG-I. By suppressing IKKα, PS-1145 interferes with the activation of NF-κB, a pathway linked to RIG-I signaling. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. PS-1145 serves as a tool for researchers studying the intricate interplay between IKKα signaling and RIG-I-mediated antiviral pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a Janus kinase (JAK) inhibitor, indirectly influences RIG-I signaling by targeting the JAK-STAT pathway. By inhibiting JAKs, Ruxolitinib interferes with the activation of STATs, downstream effectors in the RIG-I pathway. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB activation, indirectly influencing RIG-I. By preventing the phosphorylation and degradation of IκBα, BAY 11-7082 inhibits NF-κB activation and, subsequently, RIG-I expression. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a histone methyltransferase inhibitor that indirectly modulates RIG-I by influencing chromatin remodeling. By inhibiting the activity of histone methyltransferases, UNC1999 alters the epigenetic landscape, potentially affecting RIG-I expression. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 is a selective inhibitor of IKK-1, indirectly influencing RIG-I. By inhibiting IKK-1, BMS-345541 suppresses the activation of NF-κB and, subsequently, RIG-I expression. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $82.00 $306.00 | 4 | |
Nafamostat Mesylate is a serine protease inhibitor that indirectly modulates RIG-I by suppressing proteolytic activities. By inhibiting serine proteases, Nafamostat Mesylate interferes with pathways involved in viral entry and innate immune responses. This indirect modulation can impact RIG-I-mediated antiviral responses by influencing the expression of interferons and other immune response genes. | ||||||